Research programme: thapsigargin analogues - Inspyr Therapeutics

Drug Profile

Research programme: thapsigargin analogues - Inspyr Therapeutics

Alternative Names: Ac-GKAFRR-L12ADT; G-114; G-115; G-301; Plant-derived cytotoxin- Inspyr Therapeutics; Thapsigargin analogues research programme- Inspyr Therapeutics

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator GenSpera
  • Developer Inspyr Therapeutics
  • Class Lactones; Peptides; Sesquiterpenes
  • Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 01 Aug 2016 GenSpera is now called Inspyr Therapeutics
  • 06 May 2015 GenSpera has patents pending for injectable cancer compositions of thapsigargin-containing prodrugs in 17 countries, including Europe, Eurasia, Japan, China, Brazil and USA
  • 29 Apr 2015 GenSpera has patent protection for thapsigargin analogues in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top